CVS Health raises 2026 forecast after improving medical cost controls
CVS Health raised its full-year forecast on Wednesday, aided by increased first-quarter earnings in…

Intelligence analysis not yet available for this stock. Full AI-powered analysis may be available on the intelligence page.
1 signal unavailable — limited data for this stock
Trend
-38.8% vs SMA 50 · -25.3% vs SMA 200
Momentum
Analyst consensus estimates · Actuals replace estimates as reported
| Year | Revenue Est. | Rev Gth | EPS Est. | EPS Gth | Range | Analysts |
|---|---|---|---|---|---|---|
FY2023 | $85.6M $82.3M–$88.3M | — | -$0.02 | — | ±5% | Moderate3 |
FY2024 | $97.2M $96.2M–$98.1M | ▲ +13.6% | $0.04 | — | ±50% | Moderate4 |
FY2025 | $118.5M $117.3M–$119.7M | ▲ +21.9% | $0.13 | ▲ +225.0% | ±50% | Moderate3 |
CVS Health raised its full-year forecast on Wednesday, aided by increased first-quarter earnings in…

chromadex corp. is an integrated, global nutraceutical company devoted to improving the way people age. chromadex scientists partner with leading universities and research institutions worldwide to uncover the full potential of nad and identify and develop novel, science-based ingredients including pteropure® pterostilbene; purenergy®, a caffeine-pteropure® co-crystal; anthorigin™, anthocyanins and niagen® nicotinamide riboside - sold directly to consumers as the supplement, tru niagen®. tru niagen® is helping the world age better®. for more, visit www.chromadex.com like us on facebook here: https://www.facebook.com/chromadex or follow us on twitter @chromadex chromadex® is publicly-traded company (nasdaq:cdxc).